Prospective-controlled trial of Mycophenolate mofetil in patients with exacerbating chronic hepatitis B of severe degree

Objective: To prevent chronic severe hepatitis occurrence, patients with exacerbating chronic hepatitis B of severe degree were treated with Mycophenolate mofetil(MMF). Methods: 60 patients were randomized into conventional treatment group (26 cases) and MMF treatment group (34 cases). For the patients in conventional group, glutathione injection, PGE1 injection and Human Serum Albumin or Human fresh plasma were administrated daily, for the patients in MMF group, 1.0 g/d MMF were administrated orally for 30 days plus with the same treatment of conventional group. Results: The rate of convalescence in MMF treatment group is 88.2%, which was significantly higher than which of conventional group(65.4%, χ2=4.53,P0.05). The average hospitalization duration in MMF treatment group was significantly lower than which in conventional group(19.3±6.3 days vs 27.3±5.8 days, t=4.98, P0.05). The rate of deteriorating to chronic severe hepatitis in MMF group was 5.9%, which was significantly lower than which in conventional group (26.9%, χ2=5.12, P0.05). No severe adverse reaction such as complication of infections, gastrointestinal bleeding and leucopenia were found in the trial. Conclusions: MMF was effective and safe for treatment of the patients with exacerbating chronic hepatitis B of severe degree.